Prosus' $4.8B Just Eat Deal Gets EU Green Light--With One Big Catch
Warning! GuruFocus has detected 7 Warning Signs with PROSY.
The takeover could position Prosus as the world's fourth-largest food delivery group, trailing only Uber Technologies, DoorDash, and China's Meituan. Just Eat's footprint spans 17 markets, including the UK, Germany, and the Netherlands, while Prosus already controls Brazil's iFood and owns stakes in India's Swiggy and other regional platforms. Analysts suggest the combination could create a more geographically diversified portfolio at a time when the sector faces heightened competition and pressure on margins.
The food delivery industry, which expanded rapidly during the pandemic, has shifted into a phase of consolidation as players seek scale and operational efficiencies. Prosus' move could signal a strategic bet on long-term growth across multiple continents, even as regulatory oversight and price competition remain significant hurdles. The EU's conditions, coupled with Prosus' global holdings, could shape competitive dynamics across both European and emerging markets in the months ahead.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Car shipper says US tariff haze still affecting auto trade flows
By Marie Mannes STOCKHOLM (Reuters) -Europe's car exporters are still struggling with uncertainty over U.S. tariffs despite last month's trade deal, Wallenius Wilhelmsen, the operator of one of the world's largest car-carrier fleets, told Reuters on Tuesday. The U.S. and European Union struck a trade deal in late July that saw U.S. import tariffs on most goods from Europe, including cars, set at 15%. Cars had initially faced a 27.5% levy after U.S. President Donald Trump hiked tariffs this year. However, the new 15% rate has not yet been implemented for cars, meaning that Wallenius customers such as BMW, Mercedes-Benz and Volvo Cars still face the higher rate. The absence of an executive order from Trump lowering the autos tariff has left the industry holding its breath for potential last-minute changes. "So far we actually do not know exactly what the tariff level will be. Our customers do not know either, so it is too early to say what they'll do," Wallenius CEO Lasse Kristoffersen said following the company's quarterly results. While carmakers raced earlier this year to ship cars to the U.S. ahead of the tariff hike to 27.5%, the opposite happened at the start of the second quarter, Kristoffersen said. "We saw that they held more back in the start of the second quarter but that volumes increased throughout the quarter," he said. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12 minutes ago
- Yahoo
FTSE 100 rises after US-China trade truce extension; key economic data in focus
(Reuters) -Britain's blue-chip index rose on Tuesday as an extended U.S.-China tariff truce bolstered investor sentiment, while markets also focused on the day's key economic data releases. As of 0947 GMT, the blue-chip FTSE 100 gained 0.3% and the midcap index was little changed. The 90-day extension of the tariff truce between the world's two largest economies provided temporary relief to investors about global trade, effectively postponing potentially damaging triple-digit duties on Chinese exports to the U.S. In UK markets, Spirax surged 13%, leading gains on the blue-chip index, after the manufacturing group forecast organic sales growth accelerating in the second half of the year on a strong order book. Bellway inched 1.4% higher after it expects to build more homes in its new financial year. The outlook lifted the broader UK housing sector index by 0.7%. London-listed Atalaya Mining Copper climbed 7.1% after the miner raised its copper production outlook for the financial year 2025, lifting the broader industrial metal miners index by 0.5%. Economic data on the day revealed Britain's jobs market continues to soften, with payrolls declining for a sixth consecutive month and vacancies decreasing further. However, persistent wage growth underscored the Bank of England's cautious approach toward interest rate cuts. With the central bank's policymakers split over the risks of a hiring slump and a pickup in inflation pressures, the new figures pointed to a continued cooling of the labour market, albeit less sharply than in recent months. Investors now await U.S. inflation data release, which is expected to begin reflecting tariff-driven cost pressures in the world's largest economy as companies pass on expenses to consumers. Back home, the technology sector led sectoral declines, falling 0.7%. Among other stocks, gambling firm Entain dropped 3.6% despite forecasting its annual core profit outlook above market expectations. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Monica Seles - argenx 1 Monica Seles - argenx 2 Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the 'Go for Greater' MG patient support initiative at the 2025 U.S. Open Tennis Championships August 12, 2025 6:45 AM EDT Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced a partnership with nine-time Grand Slam tennis champion Monica Seles. For the first time ever, Seles is publicly speaking out about her experience with myasthenia gravis (MG) in support of argenx's Go for Greater initiative. The partnership aims to raise awareness and understanding of MG, and connect those affected with available tools and support resources. 'My MG journey over the past 5 years has not been an easy one. I felt isolated and defeated as many of the activities I enjoyed were no longer physically possible for me. I've since realized that by sharing my story, I can raise awareness of this disease, empower patients to advocate for themselves and help them connect with the MG community for support,' said Monica Seles. 'I am excited to partner with the argenx team – to inspire others living with MG to rally against this disease, pursue their goals, and live a fulfilling life. We're all in this together.' 'At argenx, we are committed to supporting the MG community by fostering understanding and connection,' said Karen Massey, Chief Operating Officer, argenx. 'We applaud Monica for sharing her personal story and are excited to collaborate with her to amplify the voices of MG patients and caregivers. Her journey and dedication to this cause will help people living with MG engage in meaningful conversations and build a supportive network around this challenging disease. Together, we hope to shine a light of understanding and support for those affected by MG.' argenx has a long-standing commitment to the MG community, helping to empower patients through programs such as Go for Greater. This program supports patients in achieving a greater quality of living by fostering connections between real people with MG, and offering support and helpful resources. In addition to the new partnership with Seles, argenx is a premier Global sponsor of the upcoming 2025 U.S. Open to amplify awareness of MG on a global stage. In the U.S., over 120,000 people are living with MG, an autoimmune, neuromuscular condition that causes a variety of symptoms, including weakness in the arms and legs, fatigue, difficulty walking, and blurred and double vision. For more information about the Go for Greater campaign, visit About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. For further information, please contact: Media contact for argenx:Ben Petokbpetok@ Media contact for Real Chemistry: Ashley Cohen ascohen@ Attachments Monica Seles - argenx 1 Monica Seles - argenx 2Sign in to access your portfolio
